Our MG community took note of the recent news regarding the latest therapy options that aim to reduce the burden of hours-long treatment delivery with IVIG. For those who are responding well to this new treatment, it’s a game changer. But we recognize that many patients are interesting in learning more, so here are some questions that have come in from the MG community with answers provided by Dr. Betty Soliven of the University of Chicago School of Medicine and a member of our Medical Advisory Board. [Click here to read more.]
